Kidney Cancer News and Research RSS Feed - Kidney Cancer News and Research

Kidney cancer is usually defined is a cancer that originates in the kidney. The two most common types of kidney cancer, reflecting their location within the kidney, are renal cell carcinoma (RCC) and urothelial cell carcinoma (UCC) of the renal pelvis.
Recycling existing drugs may help fight several types of cancer

Recycling existing drugs may help fight several types of cancer

Researchers at the University of Bergen have discovered that a drug against kidney cancer possibly can fight several types of cancer. [More]
Overweight kidney cancer patients live longer than normal-weight counterparts, study shows

Overweight kidney cancer patients live longer than normal-weight counterparts, study shows

Obesity almost always increases cancer risk and worsens outcomes, but researchers led by scientists at Dana-Farber Cancer Institute report that overweight patients with advanced kidney cancer had significantly longer survival than those who were normal or underweight. [More]
HIF-2 inhibitors could be promising target to combat kidney cancer

HIF-2 inhibitors could be promising target to combat kidney cancer

A new class of drugs called HIF-2 inhibitors is more effective and better tolerated than the standard of care drug sunitinib in treating kidney cancer, researchers with the Kidney Cancer Program at Harold C. Simmons Comprehensive Cancer Center have found. [More]
New disease gene linked to shortened telomeres appears to raise risk of pulmonary fibrosis-emphysema

New disease gene linked to shortened telomeres appears to raise risk of pulmonary fibrosis-emphysema

Johns Hopkins researchers say they have identified a new disease gene that, when mutated, appears to increase the risk in a small number of people of developing emphysema and a lung-scarring condition known as pulmonary fibrosis. [More]
Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach may prove successful in subset of adults with advanced kidney cancer

Watch-and-wait approach means some patients could delay taking highly toxic non-curative anticancer drugs that come with substantial side effects [More]
Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Cytoreductive nephrectomy can extend survival of metastatic kidney cancer patients

Surgery to remove a cancerous kidney can often lengthen the lives of patients receiving targeted therapy for metastatic kidney cancer, but only about three in ten such patients undergo the procedure, according to a new study by researchers at Dana-Farber Cancer Institute and Brigham and Women's Hospital. [More]
Cabozantinib extends advanced RCC overall survival

Cabozantinib extends advanced RCC overall survival

Patients with advanced or metastatic renal cell carcinoma derive a significant overall survival benefit from second-line treatment with the multi-tyrosine kinase inhibitor cabozantinib relative to everolimus. [More]
Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. [More]
Nivolumab drug shows better response rate in metastatic bladder cancer patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center. [More]
Advanced cancer patients lack palliative, hospice care

Advanced cancer patients lack palliative, hospice care

Medical societies, including the American Society of Clinical Oncology, recommend that patients with advanced cancer receive palliative care soon after diagnosis and receive hospice care for at least the last three days of their life. Yet major gaps persist between these recommendations and real-life practice, a new study shows. [More]
Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Ongoing treatment with nivolumab shows benefit in advanced kidney cancer patients

Only 12% of kidney cancer patients with advanced disease survive five years after their initial treatment. In a Roswell Park Cancer Institute-led study, scientists report that some patients with advanced kidney cancer who continued to receive a novel immunotherapy drug after their disease progressed saw clinical benefit. [More]
Studies explore possible link between pediatric cancer and light therapy for newborn jaundice

Studies explore possible link between pediatric cancer and light therapy for newborn jaundice

Two new studies raise enough questions about a possible link between childhood cancer and light therapy for newborn jaundice that clinicians should exercise caution in prescribing the treatment for infants whose jaundice is likely to resolve on its own, a pediatric oncologist from Dana-Farber/Boston Children's Cancer and Blood Disorders Center argues in an editorial published today by the journal Pediatrics. [More]
FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

FDA approves additional indication for Eisai's anticancer agent Lenvima in combo with Everolimus for advanced renal cell carcinoma

Eisai Co., Ltd. has announced that its U.S. subsidiary Eisai Inc. has received approval from the U.S. Food and Drug Administration (FDA) for an additional indication for Eisai's in-house developed novel anticancer agent Lenvima (lenvatinib mesylate) in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy. [More]
Long-term use of herbal remedies may not guarantee safety

Long-term use of herbal remedies may not guarantee safety

Millions of people around the world use herbal health remedies, following a tradition that began millennia ago. Many believe that herbs are safe because they have been used for many years, but researchers from Baylor College of Medicine and Stony Brook University are raising awareness that long-term use of herbal remedies is no guarantee of their safety. The invited commentary appears in EMBO reports. [More]
Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Fish oil supplements combined with anti-cancer therapy can reduce renal cell carcinoma

Researchers at UC Davis have shown that docosahexaenoic acid (DHA), a fatty acid commonly found in fish and fish oil supplements, reduces renal cell carcinoma invasiveness, growth rate, and blood vessel growth when combined with the anti-cancer therapy regorafenib. The study was published in the journal Molecular Cancer Therapeutics. [More]
Adding CYP24A1 inhibitors may improve antitumor activity of vitamin D

Adding CYP24A1 inhibitors may improve antitumor activity of vitamin D

Roswell Park Cancer Institute research on the most potent form of vitamin D, commonly called calcitriol, offers new insights into approaches that may enhance the antitumor activity of this much-studied human hormone. [More]
Scientists develop innovative technique to deliver cancer drugs deep into tumour cells

Scientists develop innovative technique to deliver cancer drugs deep into tumour cells

Scientists at Nanyang Technological University (NTU Singapore) have invented a new way to deliver cancer drugs deep into tumour cells. [More]
Study identifies genetic differences in kidney tumors of African-Americans

Study identifies genetic differences in kidney tumors of African-Americans

A University of North Carolina Lineberger Comprehensive Cancer Center-led study has identified genetic differences in tumors of African-Americans with the most common type of kidney cancer compared with whites. [More]
Six1 gene may have more substantial role in human kidney development

Six1 gene may have more substantial role in human kidney development

The best laid plans of mice and men are a bit different -- at least when it comes to kidney development. Compared to a mouse, a human has nearly 100 times more nephrons, the functional units of the kidneys. Humans may owe these abundant nephrons to a gene called SIX1, according to a new paper published in the journal Development. [More]
Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Secondary non-Hodgkin's lymphoma a concern for CML patients using TKIs

Patients with chronic myeloid leukaemia who use the tyrosine kinase inhibitor imatinib may be three to four times more likely to develop non-Hodgkin's lymphoma than the general population, study findings indicate. [More]
Advertisement